Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against Head and Neck Tumor: A phase I/II study - An immunotherapy against Head and Neck Tumor

Anti-tumor Immunotherapy Research Network, Department of Immunology, Kochi Medical School0 个研究点目标入组 65 人开始时间: 2009年4月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The following patients must be excluded: 1) Patients with uncontrollable infectious diseases (including active Tuberculosis). 2) Patients with severe complications(malignant hypertension, severe congestive heart failure, severe colonary insufficiency, Myocardial Infarction within three months, terminal stage of liver cirrhosis, uncontrollable Diabetes Mellitus, severe Pulmonary Fibrosis, active interstitial pneumonitis, etc.). 3) Patients after allogeneic bone marrow transplantation. 4) Pregnant or breast-feeding women. 5) Patients with severe psychiatric diseases. 6) Patients who have participate in any other clinical trial. 7) Patients who have previously participated in this clinical trial. 8) Any patients disqualified by a study physician because of medical, psychological, or any other reason.

发起方

Anti-tumor Immunotherapy Research Network, Department of Immunology, Kochi Medical School